Pharmacology and clinical status of gapecitabine

ONCOLOGY

Volumn 14, Issue 9, 2000, Pages 1297-1306

  Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL;

ANIMAL; BREAST TUMOR; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG SCREENING; HUMAN; METABOLISM; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS;

EID: 0034278164     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Ishikawa T, Utoh M, Sawada N, et al: Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097, 1998.
2. Ishitsuka H, Miwa M, Ishikawa T, et al: Capecitabine: An orally available fluoropyrimidine with tumor selective activity (abstract). Proc Am Assoc Cancer Res 36:407, 1995.
3. Iyer L, Ratain MJ: 5-Fluorouracil pharmacokinetics: Causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 17:494-506, 1999.